The weekly email

Every Saturday, the week's biggest stock moves, explained in plain English with sources. It's free, and it takes about five minutes to read.

  • The top moves of the week, each explained, with a link to the full story.
  • More of the week's moves in brief.
  • New pieces from Our View and the blog.

Want a daily version? Tell us.

A sample issue Sample

This sample shows the format. It covers the week of Oct 26–30, 2026, and its figures are from that week.

Top moves, explained · Week of Oct 26–30, 2026

Read time: about 5 minutes · From WhyMyStockMoved Editors

Earnings and trial results drove this week’s biggest moves. Alphabet lost about $500 billion of market value in a day as spending outran the cash it brings in. ServiceNow and Fortinet both fell 20% or more after beating forecasts. In biotech, trial data cut both ways: Genmab rose 28% while Iovance and ORIC fell by about a third.

Beyond single stocks, Brazil’s Ibovespa sank 14% after the presidential runoff, and Meta lined up $97.5 billion of stock sales to fund its AI build-out. We also published two Our View pieces and a plain-English guide to our valuation model (see the end of this email).

In this issue: 3 top moves · 6 more in brief · from Our View and the blog


1. Alphabet falls 13% as cash burn and a profit miss overshadow a cloud boom

Alphabet’s shares fell 12.6% on Thursday, Oct 29 ($324.89 to $283.82), after a third-quarter report that Reuters linked to missed revenue expectations and worsening cash burn. Advertising revenue missed expectations even though Google Cloud sales more than doubled.

Why it matters: the change is in how Alphabet pays for AI. It used to fund spending and large buybacks from its own cash; this year spending has exceeded the cash its operations generate, and it has raised debt and sold new shares.

Read the full story →


2. Iovance falls 35% after lung cancer update highlights a small subgroup

Iovance called its lung cancer trial results positive on Wednesday evening, without numbers, and the stock rose about 12% after hours. On Thursday, once the data were out, it fell 35% ($14.81 to $9.56).

Why it matters: tumors shrank in about 1 in 4 patients (24.6% of 69), close to an earlier update, but most responses came from a small group of patients identified after the fact. That result still has to be confirmed in new patients.

Read the full story →


3. Genmab jumps 28% as its head and neck cancer drug halves the risk of death

Genmab said its experimental drug petosemtamab, given with Merck’s Keytruda, cut the risk of death by half compared with Keytruda alone in a Phase 3 trial in advanced head and neck cancer. Its US shares closed up 28.3% on Tuesday, Oct 28 ($44.67 to $57.29).

Why it matters: Genmab now has a late-stage drug with survival data, and its income is concentrated. Most of its revenue comes from royalties on J&J’s Darzalex, which it expects to start declining materially in 2029.

Read the full story →


Also moved this week

  1. ServiceNow −27% (Oct 29): beat its own targets but forecast slower growth in revenue already under contract, after its stock had risen about 81% from its April 10 close. Read →
  2. Fortinet −20% (Oct 29): beat forecasts and raised its revenue outlook, but cut its forecast for service revenue (subscriptions and support). Read →
  3. ORIC −32% (Oct 26): J&J reported early results for a rival pill in the same advanced prostate cancer that ORIC’s lead drug targets. Read →
  4. Pentair +13% (Oct 27): beat profit forecasts and said pool dealers had finished cutting stock, while water peer Xylem fell 14% after a sales miss. Read →
  5. Brazil’s Ibovespa −14% (Oct 26): investors had bet on a Flávio Bolsonaro win; Lula’s runoff victory sent stocks, the currency and bonds tumbling. Read →
  6. Meta’s $97.5 billion stock sales (Explainer, developing): after years of buybacks, Meta is selling new shares and preferred stock to help fund AI data centers. Read →

From Our View and the blog

Our model turns a company’s filings and a set of written-down assumptions into a range of possible values for the end of 2030, simulating the business one quarter at a time, 50,000 times. This week we published Our View pieces on Nvidia and Viking Therapeutics, and a plain-English tour of how the model works and how we check it.

Our View is labelled opinion: results come from our assumptions, which can change and may be wrong.


Disclosure: One or more of our editors own shares of Nvidia (NVDA) and Viking Therapeutics (VKTX), named in this email, as long-term investments. None of our editors owned shares of the other companies named here at the time of writing.

You’re receiving this because you signed up for the WhyMyStockMoved weekly email at whymystockmoved.com. Unsubscribe · Questions or corrections

For education only, not investment advice. We don’t tell anyone to buy, sell or hold a stock. Prices are official closes on the dates shown; figures are from each article at publication. Full disclaimer

© 2026 WhyMyStockMoved. All rights reserved.